ATHE
Alterity Therapeutics Ltd (ATHE)
Healthcare • NASDAQ • $4.66-0.21%
- Symbol
- ATHE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.66
- Daily Change
- -0.21%
- Market Cap
- $88.12M
- Trailing P/E
- N/A
- Forward P/E
- -3.95
- 52W High
- $7.00
- 52W Low
- $2.66
- Analyst Target
- $12.00
- Dividend Yield
- N/A
- Beta
- 0.00
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as P…
Company websiteResearch ATHE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.